

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-77. (Cancelled)

78. (Previously presented) A laevorotatory enantiomer of modafinil in a polymorphic form that produces a powder X-ray diffraction spectrum comprising intensity peaks at the interplanar spacings: 8.54, 4.27, 4.02, 3.98 (Å).

79. (Previously presented) The laevorotatory enantiomer of modafinil according to claim 78, wherein the polymorphic form produces a powder X-ray diffraction spectrum further comprising intensity peaks at the interplanar spacings: 13.40, 6.34, 5.01, 4.68, 4.62, 4.44, 4.20, 4.15, 3.90, 3.80, 3.43 (Å).

80. (Previously presented) A laevorotatory enantiomer of modafinil in a polymorphic form that produces a powder X-ray diffraction spectrum comprising reflections at 15.4, 31.1, 33.1 and 33.4 degrees 2θ .

81. (Previously presented) The laevorotatory enantiomer of modafinil according to claim 80, wherein the polymorphic form produces a powder X-ray diffraction spectrum further comprising reflections at 9.8, 20.8, 26.4, 28.3, 28.7, 29.9, 31.6, 32, 34.1, 35.1 and 39 degrees 2θ .

82. (Previously presented) A pharmaceutical composition comprising a laevorotatory enantiomer of modafinil according to any one of claims 78 to 81.

83. (Previously presented) A pharmaceutical composition consisting essentially of a laevorotatory enantiomer of modafinil according to according to any one of claims 78 to 81.

84. (Currently amended) A Form I polymorph of (-)-modafinil.

85. (Currently amended) A pharmaceutical composition comprising a Form I polymorph of (-)-modafinil according to claim 84.

86. (Currently amended) A pharmaceutical composition consisting essentially of a Form I polymorph of (-)-modafinil according to claim 84.

87. (Currently amended) A process for preparing a Form I polymorph of (-)-modafinil comprising the steps of:

- (a) providing a solution of (-)-modafinil dissolved in a hot solvent;
- (b) rapidly cooling the solution from step (a) to produce crystals;
- (c) filtering the crystals;
- (d) drying the crystals; and
- (e) obtaining the crystals of said Form I polymorph of (-)-modafinil,

wherein the solvent of step (a) is selected from water, methanol, absolute ethanol, absolute ethanol plus 3% water (v/v), and ethanol denatured with toluene plus 3% water, (v/v, based on the total volume of ethanol and toluene).